Association of Vascular Parkinsonism with Impaired Neuronal Integrity in the Striatum

Overview

Journal J Neural Transm (Vienna)

Specialties Neurology
Physiology

Date 2007 Jan 18

PMID 17225931

Citations 9

Authors

M Ihara

H Tomimoto

K Ishizu

H Yoshida

N Sawamoto

K Hashikawa

H Fukuyama

Affiliations

Soon will be listed here.

Abstract

The purpose of this study is to identify the underlying differences between patients with white matter lesions (WMLs) who manifested gait disturbance suggestive of vascular parkinsonism (VaP) and those who did not, using the PET scan. Fourteen patients with extensive WMLs, as determined by MRI, were divided into two groups - 7 with gait disturbance and 7 without it. Neuronal integrity was evaluated with a PET scan using [(11)C]flumazenil (FMZ) by calculating the distribution volume of FMZ (FMZ-V(d)) in various regions of interest by non-linear curve fitting. Additionally, tracer kinetic analysis was applied for voxel-by-voxel quantification of FMZ-V(d) and data analysis was performed using statistical parametric mapping. The striatal FMZ-V(d) values were inversely correlated with the motor UPDRS scores (r = 0.70, p < 0.005), and their reductions were associated with the presence of gait disturbance. Therefore, differences in neuronal integrity in the striatum may determine whether patients with WMLs develop VaP or not.

Citing Articles

GABA Receptor Benzodiazepine Binding Sites and Motor Impairments in Parkinson's Disease.

Bohnen N, Barr J, Vangel R, Roytman S, Paalanen R, Frey K Brain Sci. 2023; 13(12).

PMID: 38137159 PMC: 10741877. DOI: 10.3390/brainsci13121711.

Effects of Cerebrovascular and Lewy Body Pathology on Parkinsonian Signs in Community-Dwelling Older Adults.

Agrawal S, Leurgans S, Nag S, Oveisgharan S, Barnes L, Bennett D Neurology. 2023; 101(7):e754-e763.

PMID: 37438127 PMC: 10437019. DOI: 10.1212/WNL.0000000000207497.

Combining CRISPR-Cas9 and brain imaging to study the link from genes to molecules to networks.

Marciano S, Ionescu T, Saw R, Cheong R, Kirik D, Maurer A Proc Natl Acad Sci U S A. 2022; 119(40):e2122552119.

PMID: 36161926 PMC: 9546570. DOI: 10.1073/pnas.2122552119.

Simultaneous PET/MRI: The future gold standard for characterizing motor neuron disease-A clinico-radiological and neuroscientific perspective.

Juengling F, Wuest F, Kalra S, Agosta F, Schirrmacher R, Thiel A Front Neurol. 2022; 13:890425.

PMID: 36061999 PMC: 9428135. DOI: 10.3389/fneur.2022.890425.

Bilateral parkinsonism in a patient with infarcts involving the unilateral basal ganglia.

Miura S, Ochi M, Ochi H, Igase M, Kawaguchi N, Miyagawa M eNeurologicalSci. 2020; 21:100291.

PMID: 33251345 PMC: 7677669. DOI: 10.1016/j.ensci.2020.100291.

References

Jellinger K . How valid is the clinical diagnosis of Parkinson's disease in the community?. J Neurol Neurosurg Psychiatry. 2003; 74(7):1005-6. PMC: 1738558. DOI: 10.1136/jnnp.74.7.1005. View

Mikolajczyk K, Szabatin M, Rudnicki P, Grodzki M, Burger C . A JAVA environment for medical image data analysis: initial application for brain PET quantitation. Med Inform (Lond). 1998; 23(3):207-14. DOI: 10.3109/14639239809001400. View

Pantoni L, Palumbo V, Sarti C . Pathological lesions in vascular dementia. Ann N Y Acad Sci. 2002; 977:279-91. DOI: 10.1111/j.1749-6632.2002.tb04827.x. View

Heiss W, Grond M, Thiel A, Ghaemi M, Sobesky J, Rudolf J . Permanent cortical damage detected by flumazenil positron emission tomography in acute stroke. Stroke. 1998; 29(2):454-61. DOI: 10.1161/01.str.29.2.454. View

Holthoff V, Koeppe R, Frey K, Paradise A, Kuhl D . Differentiation of radioligand delivery and binding in the brain: validation of a two-compartment model for [11C]flumazenil. J Cereb Blood Flow Metab. 1991; 11(5):745-52. DOI: 10.1038/jcbfm.1991.131. View

Ebersbach G, Poewe W . [Vascular parkinsonian syndrome]. Nervenarzt. 2005; 77(2):139-44, 146-7. DOI: 10.1007/s00115-005-1978-6. View

Magata Y, Mukai T, Ihara M, Nishizawa S, Kitano H, Ishizu K . Simple analytic method of 11C-flumazenil metabolite in blood. J Nucl Med. 2003; 44(3):417-21. View

Gilman S, Koeppe R, Junck L, Kluin K, Lohman M, St Laurent R . Patterns of cerebral glucose metabolism detected with positron emission tomography differ in multiple system atrophy and olivopontocerebellar atrophy. Ann Neurol. 1994; 36(2):166-75. DOI: 10.1002/ana.410360208. View

Schmidt R, Hayn M, Fazekas F, Kapeller P, Esterbauer H . Magnetic resonance imaging white matter hyperintensities in clinically normal elderly individuals. Correlations with plasma concentrations of naturally occurring antioxidants. Stroke. 1996; 27(11):2043-7. DOI: 10.1161/01.str.27.11.2043. View

10.

Winikates J, Jankovic J . Clinical correlates of vascular parkinsonism. Arch Neurol. 1999; 56(1):98-102. DOI: 10.1001/archneur.56.1.98. View

11.

Zijlmans J, Thijssen H, Vogels O, Kremer H, Poels P, Schoonderwaldt H . MRI in patients with suspected vascular parkinsonism. Neurology. 1995; 45(12):2183-8. DOI: 10.1212/wnl.45.12.2183. View

12.

De Reuck J, Siau B, Decoo D, Santens P, Crevits L, Strijckmans K . Parkinsonism in patients with vascular dementia: clinical, computed- and positron emission-tomographic findings. Cerebrovasc Dis. 2001; 11(1):51-8. DOI: 10.1159/000047611. View

13.

Abadie P, Baron J, Bisserbe J, Boulenger J, Rioux P, Travere J . Central benzodiazepine receptors in human brain: estimation of regional Bmax and KD values with positron emission tomography. Eur J Pharmacol. 1992; 213(1):107-15. DOI: 10.1016/0014-2999(92)90239-z. View

14.

Ihara M, Tomimoto H, Ishizu K, Mukai T, Yoshida H, Sawamoto N . Decrease in cortical benzodiazepine receptors in symptomatic patients with leukoaraiosis: a positron emission tomography study. Stroke. 2004; 35(4):942-7. DOI: 10.1161/01.STR.0000122624.32167.e0. View

15.

Ihara M, Fukuyama H, Lee T, Takao S, Kohara N, Shibasaki H . Delayed synaptic dysfunction of association cortices in carbon monoxide intoxication. Ann Neurol. 2002; 50(6):829-30. DOI: 10.1002/ana.10015. View

16.

Rampello L, Alvano A, Battaglia G, Raffaele R, Vecchio I, Malaguarnera M . Different clinical and evolutional patterns in late idiopathic and vascular parkinsonism. J Neurol. 2005; 252(9):1045-9. DOI: 10.1007/s00415-005-0811-2. View

17.

Maloteaux J, Luabeya M, Vanisberg M, Laterre E, Laduron P, Agid Y . Benzodiazepine receptors in normal human brain, in Parkinson's disease and in progressive supranuclear palsy. Brain Res. 1988; 446(2):321-32. DOI: 10.1016/0006-8993(88)90891-8. View

18.

Foster N, Minoshima S, Johanns J, Little R, Heumann M, Kuhl D . PET measures of benzodiazepine receptors in progressive supranuclear palsy. Neurology. 2000; 54(9):1768-73. DOI: 10.1212/wnl.54.9.1768. View

19.

Bhatia K, Marsden C . The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain. 1994; 117 ( Pt 4):859-76. DOI: 10.1093/brain/117.4.859. View

20.

Olsen R . The GABA postsynaptic membrane receptor-ionophore complex. Site of action of convulsant and anticonvulsant drugs. Mol Cell Biochem. 1981; 39:261-79. DOI: 10.1007/BF00232579. View